Jul 23, 2026 04:06PM
Jul 23, 2026 04:05PM
Jul 21, 2026 04:06PM
Jul 21, 2026 04:05PM
Jul 9, 2026 04:01PM
Jul 1, 2026 04:05PM
Jul 1, 2026 04:05PM Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Jun 15, 2026 04:11PM
Jun 15, 2026 04:10PM
Jun 15, 2026 04:06PM
Jun 15, 2026 04:05PM
Jun 15, 2026 08:36AM
Jun 15, 2026 08:35AM
Jun 15, 2026 08:30AM Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting
Jun 15, 2026 08:30AM
Jun 8, 2026 04:05PM
Jun 8, 2026 04:05PM
Jun 8, 2026 08:31AM
Jun 8, 2026 08:30AM
Jun 3, 2026 08:31AM
Jun 3, 2026 08:30AM Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
May 26, 2026 04:01PM
May 21, 2026 04:37PM
May 18, 2026 04:06PM
May 18, 2026 04:05PM
May 18, 2026 08:47AM
May 18, 2026 08:46AM
May 6, 2026 08:32AM Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY
May 6, 2026 08:30AM
May 5, 2026 04:01PM
May 5, 2026 09:00AM
May 4, 2026 08:30AM
May 4, 2026 07:30AM
May 4, 2026 07:30AM
May 1, 2026 04:06PM Neurocrine shows sustained pediatric results for CRENESSITY in two-year study
May 1, 2026 04:05PM
Apr 29, 2026 04:07PM
Apr 29, 2026 04:05PM
Apr 22, 2026 04:05PM
Apr 22, 2026 04:05PM
Apr 14, 2026 04:01PM
Apr 14, 2026 08:32AM INGREZZA shows higher treatment persistence than AUSTEDO XR in study
Apr 14, 2026 08:30AM
Apr 8, 2026 07:13AM
Apr 6, 2026 01:59PM
Apr 6, 2026 07:01AM
Apr 6, 2026 07:00AM
Mar 26, 2026 08:33AM
Mar 26, 2026 08:30AM Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Mar 17, 2026 04:09PM

326,553 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All